Tag: Cancer Gene Therapy Market – Global Cancer Gene Therapy Industry Size

Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.

Cancer Gene Therapy Market Growth Potential: How Will Market Size Change Through 2030?

The market for cancer gene therapy has experienced substantial expansion recently, projected to increase from $4.21 billion in 2025 to $4.9 billion in 2026, reflecting a compound annual growth rate (CAGR) of 16.4%. This historical growth trajectory can be attributed to several key factors, including significant strides in molecular oncology research, a broader scope of clinical trials focusing on gene therapy, heightened investments in biopharmaceutical research and development, the successful regulatory clearance of initial gene therapies, and enhancements in the manufacturing processes for therapeutic vectors.

Within the realm of cancer gene therapy, a significant expansion is anticipated in the upcoming years, projecting a market valuation of $8.9 billion by 2030, driven by a compound annual growth rate of 16.1%. This projected expansion is underpinned by several key factors: a heightened demand for customized cancer interventions, escalating investments directed towards the production capabilities for cell and gene therapies, advancements in viral vector technologies for the next generation, a growing emphasis on multi-agent oncology treatments, and the increasing integration of precise oncology methodologies. Key developments shaping this market during the forecast period encompass the ongoing creation of specialized gene therapy platforms, a greater embrace of CAR-T and TCR therapies, heightened attention on refining viral vector performance, the broadening availability of individualized cancer gene treatments, and improved incorporation of biomarker-driven treatment selection strategies.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27233&type=smp

Cancer Gene Therapy Market Industry Drivers: What Is Driving Revenue Growth?

The escalating prevalence of cancer is anticipated to serve as a significant catalyst for the expansion of the cancer gene therapy sector. Cancer, a condition defined by the rampant proliferation of aberrant cells capable of infiltrating and disseminating throughout the body, originates in diverse tissues and organs and is categorized according to its cellular or tissue origin. Factors contributing to the rising tide of cancer diagnoses include extended lifespans, as the likelihood of developing the disease escalates with advancing age. Cancer gene therapy endeavors to combat this disease by altering or substituting defective genes to halt the proliferation of cancerous cells or to bolster the body’s immune defenses against them. Illustratively, Macmillan Cancer Support, a UK entity, disclosed in August 2024 that upwards of three million individuals in the United Kingdom are currently contending with cancer, a number poised to rise to 3.5 million by 2025, 4 million by 2030, and a substantial 5.3 million by 2040, clearly underscoring the upward trend in cancer incidence as the primary driver for the cancer gene therapy market’s growth trajectory.

Cancer Gene Therapy Market Segmentation Trends And Revenue Drivers

The cancer gene therapy market covered in this report is segmented –

1) By Therapy: Gene Induced Immunotherapy, Oncolytic Virotherapy, Gene Transfer

2) By Indication: Large B-Cell Lymphoma, Multiple Myeloma, Acute Lymphoblastic Leukemia (ALL), Melanoma (lesions), Other Indications

3) By Vector Type: Lentivirus, RetroVirus And Gamma RetroVirus, Adeno-Associated Virus (AAV), Modified Herpes Simplex Virus, Adenovirus, Other Vector Types

4) By End-User: Hospitals, Research Institutes, Biopharma Companies, Cell Therapy Manufacturing Centers, Other End Users

Subsegments:

1) By Gene Induced Immunotherapy: CAR-T Cell Therapy, TCR (T-Cell Receptor) Therapy, Tumor-Infiltrating Lymphocyte (TIL) Therapy, Dendritic Cell-Based Gene Therapy, NK Cell Gene Therapy

2) By Oncolytic Virotherapy: Adenoviruses, Herpes Simplex Virus (HSV), Reovirus, Vaccinia Virus, Newcastle Disease Virus (NDV)

3) By Gene Transfer: Viral Gene Transfer, Non-Viral Gene Transfer

#Cancer Gene Therapy Market Growth Trends: What Is Influencing The Future Outlook?

Leading entities within the cancer gene therapy sector are dedicating their efforts to the creation of cutting-edge treatments, exemplified by CAR-T cell therapy, with the objective of augmenting treatment accuracy, elevating patient results, and more precisely targeting neoplastic cells while concurrently reducing harm to non-cancerous tissues. CAR-T therapy represents a sophisticated form of immunotherapy involving the genetic modification of an individual’s own immune cells to improve their capacity for identifying and eradicating malignant cells through the introduction of specific receptors. Illustratively, in April of 2024, a biotechnology firm situated in India, known as ImmunoACT, introduced NexCAR19 (actalycabtagene autoleucel), a CAR-T cell therapy for oncological conditions that originated entirely within the country. NexCAR19, engineered with the specific aim of managing B-cell lymphomas and leukemias, functions by reconfiguring the patient’s T cells to recognize and eliminate cancerous cells. This treatment, grounded in sophisticated chimeric antigen receptor (CAR) technology, is produced domestically, thereby rendering it more cost-effective and readily available compared to therapies imported from abroad. This introduction signifies a pivotal moment for India’s engagement in the worldwide arena of cancer gene therapy, underscoring substantial advancements in indigenous innovation and the provision of customized cancer care.

#Cancer Gene Therapy Market Industry Leaders: Which Organizations Are Driving Competition?

Major companies operating in the cancer gene therapy market are Bristol Myers Company, Novartis AG, GSK plc., Gilead Sciences Inc., Amgen Inc., Orchard Therapeutics Plc, AGC Biologics, Adaptimmune Limited, Sibiono, Elevate Bio Inc., Bluebird Bio Inc., Uniqure N.V., Shanghai Sunway Biotech Co. Ltd., Anges Inc., Gensight Biologics, Genelux Corporation, Cellectis, Abeona Therapeutics Inc., Kite Pharma Inc., Janssen Biotech Inc., Mustang Bio Inc., Intellia Therapeutics Inc., CRISPR Therapeutics AG, Caribou Biosciences Inc.

Access The Complete Cancer Gene Therapy Market Report:

https://www.thebusinessresearchcompany.com/report/cancer-gene-therapy-global-market-report

Cancer Gene Therapy Market Regional Analysis: Which Region Leads By Revenue?

North Americawas the largest region in the cancer gene therapy market in 2025. Asia-Pacificis expected to be the fastest-growing region in the forecast period. The regions covered in the cancer gene therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Will The Market Value Of The Cancer Gene Therapy Market Increase Between 2026 And 2030?

The cancer in vitro diagnostics (ivd) market size has experienced significant growth in recent years. This market is projected to expand from $14.32 billion in 2025 to $15.32 billion in 2026, reflecting a compound annual growth rate (CAGR) of 7.0%. The historical growth can be linked to the expansion of hospital diagnostic infrastructure, an increase in biomarker-based testing, the adoption of PCR and immunoassay technologies, an uptick in cancer screening programs, and enhanced laboratory automation.

The cancer in vitro diagnostics (ivd) market size is projected to experience significant expansion in the coming years. It is expected to reach $19.85 billion by 2030, growing at a compound annual growth rate (CAGR) of 6.7%. This forecasted growth can be attributed to the rising demand for personalized oncology diagnostics, increasing investments in genomic sequencing, the broadening of point-of-care cancer testing, the expanding integration of cloud-based diagnostic platforms, and a heightened focus on precision medicine. Noteworthy trends during the forecast period include the increasing adoption of molecular and genomic cancer testing, a rise in the use of companion diagnostics, the growing integration of AI-driven data analysis, the expansion of liquid biopsy applications, and an enhanced emphasis on early cancer detection.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27233&type=smp

What Market Drivers Are Helping Shape The Cancer Gene Therapy Market Expansion?

The escalating occurrence of cancer is projected to boost the expansion of the cancer in vitro diagnostics (IVD) market moving forward. Cancer describes the uncontrolled proliferation and spread of abnormal cells within the body, which can invade neighboring tissues and form tumors. The rising incidence of cancer is attributed to an aging global population, where longer life expectancies and decreased mortality from infectious diseases result in a larger elderly demographic more vulnerable to developing cancer. Cancer in vitro diagnostics (IVD) assists in managing cancer by enabling early and precise detection, continuous monitoring, and effective management of the disease through laboratory tests conducted on patient samples, thereby allowing timely treatment decisions and enhancing patient outcomes. For instance, in January 2023, the American Cancer Society, a US-based professional organization dedicated to eliminating cancer, reported that 1,958,310 new cancer cases and 609,820 cancer deaths are projected to occur in 2023 in the United States. Therefore, the growing incidence of cancer is propelling the growth of the cancer in vitro diagnostics (IVD) market.

How Is Segment Classification Applied In The Cancer Gene Therapy Market?

The cancer gene therapy market covered in this report is segmented –

1) By Therapy: Gene Induced Immunotherapy, Oncolytic Virotherapy, Gene Transfer

2) By Indication: Large B-Cell Lymphoma, Multiple Myeloma, Acute Lymphoblastic Leukemia (ALL), Melanoma (lesions), Other Indications

3) By Vector Type: Lentivirus, RetroVirus And Gamma RetroVirus, Adeno-Associated Virus (AAV), Modified Herpes Simplex Virus, Adenovirus, Other Vector Types

4) By End-User: Hospitals, Research Institutes, Biopharma Companies, Cell Therapy Manufacturing Centers, Other End Users

Subsegments:

1) By Gene Induced Immunotherapy: CAR-T Cell Therapy, TCR (T-Cell Receptor) Therapy, Tumor-Infiltrating Lymphocyte (TIL) Therapy, Dendritic Cell-Based Gene Therapy, NK Cell Gene Therapy

2) By Oncolytic Virotherapy: Adenoviruses, Herpes Simplex Virus (HSV), Reovirus, Vaccinia Virus, Newcastle Disease Virus (NDV)

3) By Gene Transfer: Viral Gene Transfer, Non-Viral Gene Transfer

What Trends Are Influencing The Future Of The Cancer Gene Therapy Market?

Leading firms within the cancer in vitro diagnostics market are prioritizing advancements in cancer screening, particularly through methods like blood-based colorectal cancer (CRC) screening, aimed at offering accessible, non-intrusive, and precise early detection of colorectal cancer. This type of CRC screening involves identifying molecular changes linked to cancer, specifically circulating tumor DNA (ctDNA), present in a patient’s blood sample to diagnose colorectal cancer in individuals with an average risk profile. An illustrative example is from July 2024, when Guardant Health, Inc., a precision oncology company based in the U.S., secured approval from the U.S. Food and Drug Administration (FDA) for its Guardant Shield blood test, positioning it as a primary method for colorectal cancer screening. This test operates by examining a blood specimen for particular ctDNA methylation patterns and additional markers originating from tumors. Its distinct characteristics encompass noninvasive sample collection, superior analytical precision, and seamless integration into clinical protocols for initial screening. Its utility extends to the early identification of colorectal cancer in average-risk adults. Advantages derived from its use include enhanced patient compliance, quicker detection of malignancies, a possible decrease in diagnoses at advanced stages, and qualification for Medicare reimbursement, which broadens screening accessibility for a wider population.

Which Companies Form The Competitive Landscape Of The Cancer Gene Therapy Market?

Major companies operating in the cancer gene therapy market are Bristol Myers Company, Novartis AG, GSK plc., Gilead Sciences Inc., Amgen Inc., Orchard Therapeutics Plc, AGC Biologics, Adaptimmune Limited, Sibiono, Elevate Bio Inc., Bluebird Bio Inc., Uniqure N.V., Shanghai Sunway Biotech Co. Ltd., Anges Inc., Gensight Biologics, Genelux Corporation, Cellectis, Abeona Therapeutics Inc., Kite Pharma Inc., Janssen Biotech Inc., Mustang Bio Inc., Intellia Therapeutics Inc., CRISPR Therapeutics AG, Caribou Biosciences Inc.

Access The Complete Cancer Gene Therapy Market Report:

https://www.thebusinessresearchcompany.com/report/cancer-gene-therapy-global-market-report

Which Area Represents The Largest Portion Of The Cancer Gene Therapy Market?

North America was the largest region in the cancer gene therapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer gene therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Cancer Gene Therapy Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=27233&type=smp

Browse Through More Reports Similar to the Global Cancer Gene Therapy Market 2026, By The Business Research Company

Cyclin Dependent Kinase Cdk 4 Or 6 Inhibitor Drugs Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/cyclin-dependent-kinase-cdk-4-or-6-inhibitor-drugs-global-market-report

Tyrosine Kinase Inhibitors Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/tyrosine-kinase-inhibitors-global-market-report

Janus Kinase Jak Inhibitors Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/janus-kinase-jak-inhibitors-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Expansion In Market Value Is Forecasted For The Cancer Gene Therapy Market Between 2026 And 2030?

The cancer gene therapy market size has shown rapid expansion in recent years. It is anticipated to increase from $4.21 billion in 2025 to $4.9 billion in 2026, achieving a compound annual growth rate (CAGR) of 16.4%. The surge observed in the past can be ascribed to advancements in molecular oncology research, the broader scope of clinical trials in gene therapy, rising investment in biopharmaceutical R&D, regulatory clearances for initial gene therapies, and enhanced vector manufacturing capabilities.

The cancer gene therapy market size is projected to experience substantial expansion over the upcoming years. By 2030, this market is anticipated to reach $8.9 billion, exhibiting a compound annual growth rate (CAGR) of 16.1%. This expansion during the projection period stems from various factors, including the escalating demand for tailored cancer treatments, increased investment in cell and gene therapy production, the broadening scope of next-generation viral vectors, a heightened emphasis on combination oncology therapies, and the greater uptake of precision oncology methods. Key trends anticipated in this period encompass the growing advancement of targeted gene therapy platforms, the rising acceptance of CAR-T and TCR therapies, an intensifying focus on optimizing viral vectors, the widening availability of personalized cancer gene treatments, and improved incorporation of biomarker-guided therapy selection.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/report/cancer-gene-therapy-global-market-report

Which Important Drivers Are Guiding The Cancer Gene Therapy Market Growth?

The rising occurrence of cancer is anticipated to drive the expansion of the cancer gene therapy market in the future. Cancer is defined as a condition marked by the unchecked proliferation of aberrant cells, capable of invading and spreading throughout the body, originating in different tissues and organs, and categorized by its cell or tissue type of origin. The number of cancer cases is escalating because of longer life expectancies, given that the likelihood of developing cancer increases with age. Cancer gene therapy addresses cancer by altering or substituting defective genes to halt the proliferation of cancer cells or to boost the immune system’s capacity to eliminate them. For example, in August 2024, Macmillan Cancer Support, an organization based in the UK, stated that over 3 million individuals in the UK are currently living with cancer. This number is forecasted to rise to 3.5 million by 2025, 4 million by 2030, and 5.3 million by 2040. Consequently, the rising incidence of cancer is propelling the growth of the cancer gene therapy market.

How Is The Cancer Gene Therapy Market Organized By Segment Classification?

The cancer gene therapy market covered in this report is segmented –

1) By Therapy: Gene Induced Immunotherapy, Oncolytic Virotherapy, Gene Transfer

2) By Indication: Large B-Cell Lymphoma, Multiple Myeloma, Acute Lymphoblastic Leukemia (ALL), Melanoma (lesions), Other Indications

3) By Vector Type: Lentivirus, RetroVirus And Gamma RetroVirus, Adeno-Associated Virus (AAV), Modified Herpes Simplex Virus, Adenovirus, Other Vector Types

4) By End-User: Hospitals, Research Institutes, Biopharma Companies, Cell Therapy Manufacturing Centers, Other End Users

Subsegments:

1) By Gene Induced Immunotherapy: CAR-T Cell Therapy, TCR (T-Cell Receptor) Therapy, Tumor-Infiltrating Lymphocyte (TIL) Therapy, Dendritic Cell-Based Gene Therapy, NK Cell Gene Therapy

2) By Oncolytic Virotherapy: Adenoviruses, Herpes Simplex Virus (HSV), Reovirus, Vaccinia Virus, Newcastle Disease Virus (NDV)

3) By Gene Transfer: Viral Gene Transfer, Non-Viral Gene Transfer

What Trends Are Influencing The Evolution Of The Cancer Gene Therapy Market?

Leading companies operating in the cancer gene therapy market are concentrating on developing advanced therapies, such as CAR-T cell therapy, to improve treatment precision, enhance patient outcomes, and target cancer cells more effectively while minimizing damage to healthy tissues. CAR-T therapy is a cutting-edge immunotherapy that involves engineering a patient’s immune cells with special receptors to better detect and destroy cancer cells. For instance, in April 2024, ImmunoACT, an India-based biotechnology company, introduced NexCAR19 (actalycabtagene autoleucel), which is the country’s first indigenously developed CAR-T cell therapy for cancer. Specifically designed to address B-cell lymphomas and leukemias, NexCAR19 functions by reprogramming a patient’s own T cells to identify and eliminate cancer cells. Based on advanced chimeric antigen receptor (CAR) technology, the therapy is manufactured locally, making it more affordable and accessible than imported alternatives. This launch represents a significant milestone for India’s entry into the global cancer gene therapy space, highlighting considerable advancements in domestic innovation and personalized cancer treatment.

Who Are The Industry Participants Involved In The Cancer Gene Therapy Market?

Major companies operating in the cancer gene therapy market are Bristol Myers Company, Novartis AG, GSK plc., Gilead Sciences Inc., Amgen Inc., Orchard Therapeutics Plc, AGC Biologics, Adaptimmune Limited, Sibiono, Elevate Bio Inc., Bluebird Bio Inc., Uniqure N.V., Shanghai Sunway Biotech Co. Ltd., Anges Inc., Gensight Biologics, Genelux Corporation, Cellectis, Abeona Therapeutics Inc., Kite Pharma Inc., Janssen Biotech Inc., Mustang Bio Inc., Intellia Therapeutics Inc., CRISPR Therapeutics AG, Caribou Biosciences Inc.

Get The Full Cancer Gene Therapy Market Report:

https://www.thebusinessresearchcompany.com/report/cancer-gene-therapy-global-market-report

Which Region Leads The Cancer Gene Therapy Market In Overall Market Size?

North America was the largest region in the cancer gene therapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer gene therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Cancer Gene Therapy Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/cancer-gene-therapy-global-market-report

Browse Through More Reports Similar to the Global Cancer Gene Therapy Market 2026, By The Business Research Company

Farm Equipment Rental Market Report 2026

https://www.thebusinessresearchcompany.com/report/farm-equipment-rental-global-market-report

Commercial Fan And Air Purification Equipment Market 2026

https://www.thebusinessresearchcompany.com/report/commercial-fan-and-air-purification-equipment-market

Commercial Fan And Air Purification Equipment Market 2026

https://www.thebusinessresearchcompany.com/report/commercial-fan-and-air-purification-equipment-market

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model